Skip to main content
Top
Published in: Internal and Emergency Medicine 8/2022

14-10-2022 | Community-Acquired Pneumonia | IM - ORIGINAL

Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study

Authors: Dong-Xu Hua, Kai-Shu Ma, Jia-Yi Cheng, Ying Liu, Jing Sun, Qi-Yuan He, You-Peng Deng, Jin Yang, Lin Fu, Hui Zhao

Published in: Internal and Emergency Medicine | Issue 8/2022

Login to get access

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) can trigger the apoptosis pathways through binding to relative death receptors. However, the relationship of TRAIL with community-acquired pneumonia (CAP) was unclear. This study aims at exploring the relationships between circulatory TRAIL with severity and prognosis in CAP patients through a prospective cohort study. The whole of 239 CAP patients was enrolled. Demographic characteristics and clinical information were analyzed. TRAIL and inflammatory cytokines were measured using enzyme-linked immunosorbent assay (ELISA). Circulatory TRAIL was gradually increased in accord with CAP severity scores. Spearman or Pearson correlative analysis indicated that circulatory TRAIL was strongly associated with physiologic indicators among CAP patients. Mixed logistic and linear regression models revealed that circulatory TRAIL was positively correlated with the severity scores in CAP patients. After adjusting for confounders, higher levels of circulatory TRAIL on admission significantly elevated the risks of ICU admission, mechanical ventilation, longer hospital stays, or even death during hospitalization. The predictive capacities of serum TRAIL for death were higher compared with CAP severity scores, inflammatory and infectious indicators. There are obviously positive dose-response relationships between circulatory TRAIL on admission with the severity and poor prognostic outcomes in CAP patients. Circulatory TRAIL on admission may be used as a potential biomarker in predicting the severity and poor prognosis for CAP patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2(Suppl 2)):S27-72. https://doi.org/10.1086/511159CrossRefPubMed Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2(Suppl 2)):S27-72. https://​doi.​org/​10.​1086/​511159CrossRefPubMed
3.
go back to reference Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R et al (2009) Severe community-acquired pneumonia: validation of the infectious diseases society of America/American thoracic society guidelines to predict an intensive care unit admission. Clin Infect Dis 48(4):377–385. https://doi.org/10.1086/596307CrossRefPubMed Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R et al (2009) Severe community-acquired pneumonia: validation of the infectious diseases society of America/American thoracic society guidelines to predict an intensive care unit admission. Clin Infect Dis 48(4):377–385. https://​doi.​org/​10.​1086/​596307CrossRefPubMed
17.
go back to reference Droemann D, Hansen F, Aries SP, Braun J, Zabel P, Dalhoff K, Schaaf B (2006) Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Respiration 73(3):340–346. https://doi.org/10.1159/000090342CrossRefPubMed Droemann D, Hansen F, Aries SP, Braun J, Zabel P, Dalhoff K, Schaaf B (2006) Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Respiration 73(3):340–346. https://​doi.​org/​10.​1159/​000090342CrossRefPubMed
36.
go back to reference Akram KM, Lomas NJ, Forsyth NR, Spiteri MA (2014) Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int J Clin Exp Pathol 7(2):552–564PubMedPubMedCentral Akram KM, Lomas NJ, Forsyth NR, Spiteri MA (2014) Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int J Clin Exp Pathol 7(2):552–564PubMedPubMedCentral
44.
go back to reference Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G et al (2010) The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 25(8):2596–2602. https://doi.org/10.1093/ndt/gfq042CrossRefPubMed Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G et al (2010) The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 25(8):2596–2602. https://​doi.​org/​10.​1093/​ndt/​gfq042CrossRefPubMed
Metadata
Title
Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study
Authors
Dong-Xu Hua
Kai-Shu Ma
Jia-Yi Cheng
Ying Liu
Jing Sun
Qi-Yuan He
You-Peng Deng
Jin Yang
Lin Fu
Hui Zhao
Publication date
14-10-2022
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 8/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-022-03086-7

Other articles of this Issue 8/2022

Internal and Emergency Medicine 8/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.